#Taiwan #San Diego #Startup Island #BIO 2026 #Taiwan Biotech

Expansion of Taiwan's Biotech Sector at BIO 2026

In a remarkable display of growth, six Taiwanese biomedical startups have successfully engaged in over 100 one-on-one meetings with global pharmaceutical companies, investors, and research organizations at BIO International Convention 2026. The event, held from June 22 to 25 in San Diego, California, served as a significant platform for these startups to forge valuable connections and explore opportunities for strategic partnerships and international market expansion.

The delegation from Taiwan was prominently supported by the National Development Council's national startup initiative, Startup Island TAIWAN, and led by the Development Center for Biotechnology (DCB). Among the startups participating were AB DigiHealth Inc., AcadeMab Biomedical INC., PlasmonicTron Co., Ltd., Taiwan Universe BioMedicine Inc., CancerFree Biotech, and Precisemab Biotech Co., Ltd. Each of these entities showcased Taiwan’s robust capabilities in areas such as precision health, oncology therapeutics, organoid platforms, vaccine development, and next-generation antibody technologies.

Throughout the convention, representatives from these companies reported considerable interest from key international sectors. For instance, AB DigiHealth focused on forming strategic alliances to enhance the global reach of its AI-based reproductive health solutions. Similarly, CancerFree Biotech engaged in discussions aimed at the licensing and application of its advanced AI-enabled organoid technologies in drug development.

Moreover, Taiwan Universe BioMedicine sought collaborations with global pharmaceutical leaders for vaccine co-development, while AcadeMab Biomedical negotiated potential licensing arrangements and fundraising efforts. PlasmonicTron utilized the occasion to connect with pharmaceutical companies and Contract Research Organizations (CROs) to explore scalable organoid applications and commercialization strategies.

Precisemab Biotech generated significant interest in its innovative Universal Antibody Lock™ platform, which facilitates the selective activation of antibodies at disease sites, thus enhancing therapeutic efficacy. This interest led to discussions on clinical collaborations and licensing.

As the largest biotechnology partnering event in the world, BIO 2026 provided an invaluable stage for Taiwanese startups, enabling them to connect with industry leaders and investors. These extensive interactions not only highlighted the growing importance of Taiwan in the global biotech landscape but also underscored the transformative role of Startup Island TAIWAN in fostering international partnerships and accelerating the commercialization of innovative biotech solutions.

About Startup Island TAIWAN

Startup Island TAIWAN is dedicated to enhancing the startup ecosystem in Taiwan, bridging local innovations with global opportunities. Through strategic partnerships and various events, it effectively showcases Taiwan's technological advancements and entrepreneurial spirit.

Featured Companies:

• - AB DigiHealth Inc.: Specializes in developing AI-powered reproductive healthcare solutions. Their flagship product integrates genomic data with maternal health parameters to optimize embryo selection processes.
• - AcadeMab Biomedical Inc.: A clinical-stage biotechnology firm focusing on innovative therapies for cancer stem cells. They are advancing their lead candidate through clinical trials.
• - PlasmonicTron Co. Ltd.: Offers AI-enabled organoid manufacturing, standardizing production processes to support drug discovery and regenerative medicine.
• - Taiwan Universe BioMedicine Inc.: Develops advanced vaccines addressing unmet medical needs with an emphasis on safety and cost-effectiveness.
• - CancerFree Biotech: Pioneers precision oncology solutions to personalize drug testing through patient-derived organoids.
• - Precisemab Biotech Co. Ltd.: Focusing on next-gen antibody engineering, they are exploring licensing and collaboration opportunities globally.

This showcase at BIO 2026 underlines the vibrant biotech innovation pipeline in Taiwan, demonstrating the potential for significant advancements in healthcare solutions across the globe.